U.S. market Closed. Opens in 16 hours 51 minutes

ZNTL | Zentalis Pharmaceuticals, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
RevenueN/AN/AN/AN/AN/A14.00K
Cost of Revenue1.39M1.43M544.00K160.00K111.00KN/A
Gross Profit-1.39M-1.43M-544.00K-160.00K-111.00K14.00K
Operating Expenses252.55M227.29M216.54M118.79M46.84M23.80M
Selling, General & Admin62.96M54.55M40.94M33.89M8.46M4.88M
Research & Development189.59M172.73M175.60M84.90M38.39M18.92M
Other Operating Expenses45.57MN/AN/AN/A-16.00KN/A
Operating Income-253.94M-227.29M-216.54M-118.79M-46.84M-23.78M
Other Expenses / Income-22.95M5.99M51.98M683.00K482.00K355.00K
Before Tax Income-276.89M-221.30M-164.56M-118.10M-46.36M-23.43M
Income Tax Expenses-601.00K-469.00K-297.00K444.00K15.00K4.00K
Net Income-292.19M-220.83M-164.26M-118.55M-46.38M-21.07M
Interest ExpensesN/A2.58MN/AN/AN/AN/A
Basic Shares Outstanding65.41M52.86M42.69M41.04M35.88M18.06M
Diluted Shares Outstanding65.41M52.86M42.69M41.04M35.88M18.06M
EBITDA-252.55M-233.27M-268.52M-119.47M-46.73M-23.73M
EBITDA Margin0.00%0.00%0.00%0.00%0.00%-169,514.29%
EBIT-292.79M-218.72M-164.56M-118.10M-46.36M-21.06M
EBIT Margin0.00%0.00%0.00%0.00%0.00%-150,450.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙